Welcome to our dedicated page for Rapid Micro Biosystems news (Ticker: RPID), a resource for investors and traders seeking the latest updates and insights on Rapid Micro Biosystems stock.
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) is a life sciences technology company that regularly issues news and updates related to its automated microbial quality control (MQC) solutions for pharmaceutical and biopharmaceutical manufacturing. Company press releases focus on the performance and adoption of its flagship Growth Direct system, which automates and modernizes manual MQC testing workflows used in large and complex pharmaceutical manufacturing operations across the globe.
News for RPID often covers quarterly and annual financial results, including product revenue, service revenue, and recurring revenue from consumables and annual service contracts. The company highlights metrics such as system placements, customer system validations, recurring revenue growth, and record consumable revenue. Updates have also described record multi-system orders from an existing Top 20 global biopharma customer to automate a global manufacturing network across North America, Europe, and Asia Pacific.
Investors and industry followers can also expect announcements about capital structure and financing, such as the disclosed five-year, $45 million term loan facility with Trinity Capital Inc., as well as news on the company’s financial position and outlook. Additional news items include participation in major healthcare and investor conferences, including the J.P. Morgan Healthcare Conference, the Stifel Healthcare Conference, and the H.C. Wainwright Global Investment Conference, where management presents and engages with analysts and investors.
This RPID news page on Stock Titan aggregates these types of updates so readers can quickly review earnings announcements, financing developments, system placement milestones, and conference participation related to Rapid Micro Biosystems. Users interested in the evolution of automated microbial quality control in biopharma manufacturing can monitor this feed for the company’s latest publicly released information.
Rapid Micro Biosystems (Nasdaq: RPID) announced that CEO Robert Spignesi will present at the 2022 PDA/FDA Joint Regulatory Conference on September 14. His session, titled “The Microbiology Lab of the 21st Century”, will address challenges faced by global pharmaceutical companies and the role of automation and digitization in modernizing microbial quality control in manufacturing. The session starts at 7:15 AM ET and will last approximately 25 minutes, followed by a Q&A with Kham Nguyen.
Investors can register for a live webcast.
Rapid Micro Biosystems reported Q2 2022 commercial revenue of $3.9 million, down from $5.7 million in Q2 2021. Recurring revenue grew 31% to $2.5 million, now representing 65% of total revenue. The company has lowered its full-year revenue guidance to at least $17.0 million, citing slower system placements and macroeconomic uncertainties. An organizational restructuring plan has been announced, aiming for $8.0 - $9.0 million in annual cost savings. The company rejected a takeover proposal from Kennedy Lewis Investment Management.
Rapid Micro Biosystems, Inc. (Nasdaq: RPID) has announced its Board of Directors' unanimous rejection of a non-binding proposal from Kennedy Lewis Investment Management to acquire the company for $5.00 per share. The Board has engaged Morgan Stanley as financial advisor to explore strategic alternatives, including potential sale or merger. Additionally, a limited-duration stockholder rights plan was adopted to protect shareholder value, with rights triggered if ownership exceeds 15%. The plan will expire after the 2023 Annual Meeting unless approved by shareholders.
Rapid Micro Biosystems (Nasdaq: RPID) is set to release its second quarter 2022 financial results on August 12, prior to market open. A management webcast will follow at 8:30 a.m. EST, accessible on the Company’s website. The Company specializes in automation solutions for healthcare product manufacturing, enhancing microbial quality control testing through its flagship Growth Direct System. This innovation improves efficiency, accuracy, and compliance, supporting the safe production of biologics, vaccines, and therapies.
Rapid Micro Biosystems has received an unsolicited proposal from Kennedy Lewis Investment Management to acquire all outstanding shares for $5.00 per share in cash. The Board of Directors will review this non-binding offer in line with its fiduciary duties, emphasizing that shareholders do not need to take any action at this time. The company specializes in automation solutions aimed at enhancing the manufacturing and release processes for healthcare products, including biologics and vaccines, and is headquartered in Lowell, Massachusetts.
Kennedy Lewis Investment Management LLC is proposing to acquire Rapid Micro Biosystems (RPID) for $5.00 per share in cash, reflecting a 57% premium over its last closing price of $3.18 on June 29, 2022. As of now, Kennedy Lewis holds approximately 14.14% of RPID's Class A common stock. The firm believes that taking RPID private could enhance its operational value and support stakeholders. The proposal is contingent upon due diligence and final agreement terms, which Kennedy Lewis is prepared to pursue swiftly.
Rapid Micro Biosystems reported first quarter 2022 commercial revenue of $4.2 million, down from $4.8 million in Q1 2021.
Recurring commercial revenue grew by 66% to $2.7 million. The company reaffirmed its full-year 2022 revenue outlook of $27 million to $32 million, expecting growth of 25% to 50% year-over-year. The net loss decreased to ($14.9 million) from ($22.1 million) in Q1 2021. Cash and investments totaled $184.2 million, with no debt. System placements are anticipated to peak in Q4 2022 as access to customer sites improves.
Rapid Micro Biosystems, Inc. (Nasdaq: RPID) will announce its first quarter 2022 financial results on May 10, 2022, before the market opens. A webcast conference call hosted by management will follow at 8:30 a.m. EDT, accessible via the company’s investor relations website. The company specializes in life sciences technology, focusing on automation solutions that enhance the manufacturing and quality control processes for healthcare products, including biologics and vaccines. Their Growth Direct System modernizes microbial quality control testing across pharmaceutical manufacturing globally.
Rapid Micro Biosystems (Nasdaq: RPID) reported a fourth quarter total revenue of $5.2 million for 2021, maintaining the same level as Q4 2020. Full year revenue reached $23.2 million, a 44% increase from 2020. Commercial revenue for the year was $21.6 million, up 54%, with recurring revenue showing remarkable growth of 100%. The company has reaffirmed its 2022 commercial revenue outlook of $27 million to $32 million, suggesting growth between 25% and 50%.
Rapid Micro Biosystems (Nasdaq: RPID) announced its participation in the Cowen 42nd Annual Health Care Conference, scheduled for March 8, 2022, at 10:30 a.m. EST. CEO Rob Spignesi and CFO Sean Wirtjes will engage in a virtual Q&A session, accessible via a live webcast on the company's website. The session will also be archived for 90 days. The company specializes in automation solutions for healthcare product manufacturing, focusing on enhancing quality control processes through its flagship product, the Growth Direct System.